BenevolentAI

What is BenevolentAI?

BenevolentAI is a global clinical AI and biotechnology company founded in 2013. The platform was created to accelerate the discovery and development of new medical treatments, drastically reducing the time and cost that the traditional pharmaceutical industry spends on laboratory testing before starting clinical trials.

How it works

The BenevolentAI platform (known as the Benevolent Platform) continuously ingests and processes millions of global scientific data sources: medical papers, clinical trials, patents, genetic sequencing, and molecular structures. The AI correlates this data into a giant "Knowledge Graph," identifying hidden biological targets associated with specific diseases and generating proposals for new chemical molecules with therapeutic potential to combat them.

Key Features

• Biomedical Knowledge Graph: A massive neural network mapping the complex relationships between genes, proteins, diseases, and chemical compounds.
• Therapeutic Target Identification: Predictive AI algorithms that suggest new biological targets for treating difficult-to-cure diseases (such as ALS and inflammatory diseases).
• AI-Assisted Molecule Design: Computational chemistry generative models that design new molecules with ideal absorption and safety properties.
• In-house Laboratory Validation: Dedicated laboratory facilities in the UK that test and validate molecules proposed by the AI in an integrated manner.

Who is it for?

• Large Pharmaceutical Companies (Big Pharma) looking to accelerate their research and development (R&D) phases.
• Scientific and Medical Research Institutes focused on discovering treatments for rare or neglected diseases.
• Biologists and Computational Chemists who use predictive modeling in drug development.

Pricing

Pros and Cons

Pros:

• Fantastic integration between advanced computer science and practical validation in real biology labs.
• Proven track record of rapid identification of new treatments (such as proposing the use of baricitinib against COVID-19 in 2020).
• Considerably reduces the failure rate in selecting drug candidates.

Cons:

• Platform restricted to large-scale corporate and commercial partnerships.
• The development of new drugs is still subject to long and necessary regulatory timelines and clinical trials in humans.

Alternatives to BenevolentAI

If you are looking for AI platforms applied to drug discovery and biotechnology, the main alternatives are Recursion Pharmaceuticals, Exscientia, Insilico Medicine, and the AlphaFold technology by Google DeepMind.